Product Description: Lixudebart is a humanized immunoglobulin G1-kappa, anti-CLDN1 monoclonal antibody[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 36, No. 4, 2022.
CAS Number: 2749515-10-2
Molecular Weight: N/A
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: Others